InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018
August 06, 2018 16:05 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
July 31, 2018 08:30 ET
|
ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
July 23, 2018 08:41 ET
|
InspireMD, Inc.
Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
June 11, 2018 09:53 ET
|
InspireMD, Inc.
Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
May 29, 2018 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Zenosense, Inc.: MIDS Shareholder Update
May 24, 2018 08:43 ET
|
Zenosense, Inc.
VALENCIA, SPAIN, May 24, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and...
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
May 10, 2018 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Cardiometabolic Health Congress (CMHC) Concludes CMHC West 2018
May 08, 2018 10:25 ET
|
Cardiometabolic Health Congress
Boca Raton, May 08, 2018 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress concluded its event CMHC West: Advancing Cardiometabolic Health from East to West on Saturday, May 5th at Wynn Las Vegas....
Dr. Elaine Jeter Joins Aegis Sciences Corporation as Senior Medical Policy Advisor
April 24, 2018 12:55 ET
|
Aegis Sciences Corporation
NASHVILLE, Tenn., April 24, 2018 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare sciences and forensic toxicology laboratory, is pleased to announce that Dr. Elaine Jeter has...
ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement
April 23, 2018 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 23, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...